Virtual Reality Exposure Therapy for Gambling Disorder

Gambling Disorder Clinical Trial

— VIRET-GAD  

Official title:

Virtual Reality Exposure Therapy for Gambling Disorder: Randomized Controlled Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04467502
• Other study ID #: 2020_02
• Secondary ID: 2020-A02710-39
• Status: Not yet recruiting
• Phase: N/A
• Start date: January 2024
• Est. completion date: July 2026

Study information

• Verified date: January 2024
• Source: University Hospital, Lille
• Contact: Pierre TAQUET, PhD
• Phone: 0320445838
• Email: pierre.taquet[@]chru-lille.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Gambling disorder (GD) is recognized as an addictive disorder in the DSM-5. Craving is a core phenomenon in addiction that can lead to relapse in problem gambling for pathological gamblers. Exposure Therapy (ET) focuses on craving in addiction treatment. ET in Cognitive-Behavioral Therapy (CBT) is based on classical conditioning that addresses the association between contextual cues and the craving response. ET helps the patient to reduce craving when faced with cues triggering craving. ET includes in vivo exposure and imaginal exposure. The literature recommends being as close as possible to the context of addiction to facilitate the extinction of craving but in vivo ET is complicated to perform. For GD, in outpatient consultation, bringing a patient to a casino presents obstacles (e.g., time, human and financial cost, agreement with casino for therapy).

The study will be to assess the effectiveness of Virtual Reality Exposure Therapy (VRET) in a virtual gambling environment. Various trials show that VRET is no more or less effective than classical ET in CBT but has other advantages for motivation to treatment. This research aims to compare efficacy between CBT with VRET and CBT with imaginal exposure for treatment of GD in a multicenter, randomized, controlled, non-inferiority clinical trial.

Description:

Main aim:

Show, within patients seeking care for GD, that VRET integrated with CBT is non-inferior to imaginal ET integrated with CBT on GD symptom reduction at the end of 12 treatment sessions.

Secondary objectives:

1. Show that VRET integrated with CBT is non-inferior to imaginal ET integrated with CBT on GD symptom reduction during the first 12 months post-treatment.

2. Compare the effect of the two therapeutic strategies on GD symptoms (measured by complementary assessments to that used in the main aim), at the end of treatment and during the first 12 months post-treatment.

3. Show the efficacy of VRET integrated with CBT compared to imaginal ET integrated with CBT on gambling behavior, craving, and gambling-related cognitions at the end of treatment and during the first 12 months post-treatment.

4. Show the efficacy of VRET integrated with CBT compared to imaginal ET integrated with CBT on the evolution of anxiety and depressive symptoms at the end of treatment and during the first 12 months post-treatment.

5. Compare the quality of the two therapeutic strategies at the end of treatment.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 124
• Est. completion date: July 2026
• Est. primary completion date: July 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Seek treatment for GD within one of health care facilities participating in the research (first request for treatment and not patients already receiving treatment for gambling disorder in the care center).

• Meet a current diagnosis of gambling disorder according to DSM-5 criteria and with a South Oaks Gambling Screen (SOGS) score = 5

• Meet a casino gambling behavior with a casino gambling frequency = 1 time every two months during the last 12 months

• Have a sufficient understanding of French for therapy

• Beneficiary of the French social security system

• Give an informed consent to participate

• Willing to comply with all study procedures and duration

Exclusion Criteria:

• Visual disturbance making impossible the use of virtual reality equipment (e.g. advanced retinal degeneration, central scotoma, age-related macular degeneration)

• Pregnant woman

• Minor or adult under guardianship, conservatorship, under judicial protection, persons deprived of their liberty

• Balance disorder (e.g. cerebellar disorder, inner ear disorder)

• Photosensitive epilepsy

• Refusal to participate

Related Conditions & MeSH terms

• Gambling
• Gambling Disorder

Intervention

Other:
• cognitive-behavioral therapy for gambling disorder
6 sessions of cognitive-behavioral therapy for gambling disorder
• imaginal exposure therapy focus on gambling cues
6 sessions of imaginal exposure therapy focus on gambling cues
• virtual reality exposure therapy focus on gambling cues
6 sessions of virtual reality exposure therapy focus on gambling cues

Locations

Country	Name	City	State
France	CHU Amiens-Picardie	Amiens
France	CH Boulogne sur mer CSAPA	Boulogne-sur-Mer
France	CHU de Caen	Caen
France	Hôpital Fontan, CHU lille	Lille
France	Assoriation Cédragir Lomme CSAPA	Lomme
France	CH de l'arrondissement de Montreuil / CSAPA	Montreuil sur Mer
France	CHU Rouen	Rouen
France	CH de Saint Amand les Eaux	Saint-Amand-les-Eaux
France	CH Seclin Carvin CSAPA	Seclin
France	Association GREID ValenciennesCSAPA	Valenciennes

Sponsors (2)

Lead Sponsor	Collaborator
University Hospital, Lille	Ministry of Health, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in South Oaks Gambling Screen (SOGS) between baseline and end of treatment (12 sessions, 6 months)	The SOGS is a 20-item instrument used to screen for pathological gambling. The SOGS is scored by summing the number of items endorsed out of 20 and a cut score of 5 or more indicates a probable pathological gambling. The score ranges from 0 to 20.	at the end of treatment (an average of 6 months)
Secondary	Change in South Oaks Gambling Screen (SOGS) between baseline and follow-up at 3, 6 and 12 months after the end of treatment	The SOGS is a 20-item instrument used to screen for pathological gambling. The SOGS is scored by summing the number of items endorsed out of 20 and a cut score of 5 or more indicates a probable pathological gambling. The score ranges from 0 to 20.	at baseline, and through study completion, an average of 18 months
Secondary	Change in gambling disorder symptoms between baseline, end of treatment and follow-up assessed by the following criteria: number of DSM-5 criteria for GD	Nine criteria for gambling disorder are described in DSM-5. The endorsement of 4-5 criteria means the presence of a mild gambling disorder, 6-7 criteria a moderate gambling disorder and 8-9 criteria a severe gambling disorder. The score ranges from 0 to 9 criteria.	at baseline, and through study completion, an average of 18 months
Secondary	Change in gambling disorder symptoms between baseline, end of treatment and follow-up assessed by the following criteria: Problem Gambling Severity Index (PGSI)	The PGSI consists of nine items to assess level of risk for problem gambling. Cut-off scores are 1-2 for low-risk gamblers, 3-7 for moderate-risk gamblers and 8 or more for problem-gamblers. Non-problem gamblers correspond to 0. The score ranges from 0 to 27.	at baseline, and through study completion, an average of 18 months
Secondary	Change in gambling behavior assessed by gambling frequency during the last month		at baseline, and through study completion, an average of 18 months
Secondary	Change in gambling behavior assessed by amount of money spent in gambling during the last month		at baseline, and through study completion, an average of 18 months
Secondary	Change in gambling behavior assessed by time spent gambling during the last month		at baseline, and through study completion, an average of 18 months
Secondary	Change in frequency subscale of gambling Craving Experience Questionnaire (g-CEQ)	The frequency subscale of gambling Craving Experience Questionnaire assesses the frequency of craving for gambling during the last week. This questionnaire consists of nine items. A high score means a high frequency of craving during the last week. The score ranges from 0 to 90.	at baseline, and through study completion, an average of 18 months
Secondary	Change in craving reactivity to gambling cues		at baseline, and through study completion, an average of 18 months
Secondary	Number of craving episodes using daily craving assessed by participants		up to 6 months during the treatment
Secondary	Cumulative duration of craving episodes using daily craving assessed by participants		up to 6 months during the treatment
Secondary	Change in gambling-related cognitions assessed by Gambling-Related Cognitions Scale (GRCS)	The French version of the Gambling-Related Cognitions Scale consists of 23 items to assess various cognitions related to gambling. A high score means that gambling-related cognitions are typical cognitions of problem gamblers. The score ranges from 23 to 161.	at baseline, and through study completion, an average of 18 months
Secondary	Change in depressive symptoms assessed by Beck Depression Inventory short-form (BDI-SF)	Beck Depression Inventory short-form consists of 13 items to assess depressive symptoms. A high score means a high level of depressive symptoms. The score ranges from 0 to 39.	at baseline, and through study completion, an average of 18 months
Secondary	Change in anxiety symptoms assessed by State-Trait Anxiety Inventory (STAI)	State-Trait Anxiety Inventory consists of 20 items to assess state-anxiety and 20 items to assess trait-anxiety. A high score means a high level of anxiety symptoms. The score ranges from 20 to 80 both for state-anxiety and trait-anxiety.	at baseline, and through study completion, an average of 18 months
Secondary	Rate of patients who attended the 12 sessions (6 months)	Quality of the two therapeutic strategies	up to 6 months during the treatment